Patents Assigned to Biomeasure, Inc.
-
Publication number: 20040018981Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.Type: ApplicationFiled: July 28, 2003Publication date: January 29, 2004Applicant: Biomeasure Inc., a Massachusetts corporationInventor: Zheng Xin Dong
-
Publication number: 20030092800Abstract: A copolymer comprising an N-acylated derivative, and a composition comprising said copolymer and a polypeptide, said polypeptide comprising at least one effective ionogenic amine, wherein at least 50 percent, by weight, of said polypeptide present in said composition is ionically bound to said polymer.Type: ApplicationFiled: September 20, 2002Publication date: May 15, 2003Applicant: Biomeasure, Inc.Inventors: Shalaby W. Shalaby, Steven A. Jackson, Francis X. Ignatious, Jacques-Pierre Moreau, Ruth M. Russell
-
Publication number: 20030050436Abstract: A linear (i.e., non-cyclic) analog of biologically active amphibian bombesin, mammalian gastrin-releasing peptide (GRP), or mammalian growth hormone releasing factor (GRF), having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell. Cleavage of a peptide bond in the active site of naturally occurring bombesin, GRP, or GRF is unnecessary for in vivo biological activity. The analog has one of the following modifications: (a) a deletion of an amino acid residue within the active site and a modification of an amino acid residue outside of the active site, (b) a replacement of two amino acid residues within the active site with a synthetic amino acid, a &bgr;-amino acid, or a &ggr;-amino acid residue, or (c) a non-peptide bond instead of a peptide bond between an amino acid residue of the active site and an adjacent amino acid residue.Type: ApplicationFiled: October 23, 2001Publication date: March 13, 2003Applicant: Biomeasure Inc., Massachusetts corporationInventors: David H. Coy, Jacques-Pierre Moreau, Sun Hyuk Kim
-
Publication number: 20030004342Abstract: The present invention is directed to imidazolyl derivatives of formula (II), wherein the variables are defined in the specification, which are useful as prenyl transeferase inhibitors.Type: ApplicationFiled: May 20, 2002Publication date: January 2, 2003Applicant: Biomeasure, Inc., a Massachusetts corporationInventors: Zheng Xin Dong, Yeelana Shen
-
Patent number: 6150333Abstract: The present invention is directed to a method of treating one or more of the following disease and/or conditions, which comprises administering to a patient in need thereof the compound H-.beta.-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH.sub.2, where the Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, most preferably the acetate salt of the compound, in the treatment of certain diseases and/or conditions such as gastroenterological conditions and/or diseases, endocrinological diseases and/or conditions, various types of cancers and conditions associated with cancer such as cancer cachexia and in the treatment of hypotension and panic attacks.Type: GrantFiled: July 26, 1999Date of Patent: November 21, 2000Assignee: Biomeasure, Inc.Inventor: Jacques-Pierre Moreau
-
Patent number: 6087337Abstract: A method of treating a mammal suffering from benign or malignant proliferative skin disease, e.g., melanoma or malignant skin metastases of melanoma, by topically administering to the mammal at the site of said diseased skin an effective amount of a somatostatin analog containing six or more amino acids.Type: GrantFiled: July 9, 1993Date of Patent: July 11, 2000Assignee: Biomeasure Inc.Inventors: Arthur E. Bogden, Jacques-Pierre Moreau
-
Patent number: 6083915Abstract: A method of treating liver cancer involving administration to the subject a therapeutically effective amount of a bombesin analog.Type: GrantFiled: May 10, 1991Date of Patent: July 4, 2000Assignees: Biomeasure, Inc., The Administration of the Tulane Educational FundInventors: Arthur E. Bogden, David H. Coy, Sun Hyuk Kim, Jacques-Pierre Moreau
-
Patent number: 6001801Abstract: A cyclic peptide analog of somatostatin wherein a disulfide bond links the N-terminus residue and the C-terminus residue.Type: GrantFiled: January 13, 1998Date of Patent: December 14, 1999Assignees: Biomeasure, Inc., Tulane Univ. Medical Ctr.Inventors: David H. Coy, John E. Taylor
-
Patent number: 5969095Abstract: Peptide variants of fragment (1-34) of parathyroid hormone, in which at least one of the amino acid residues at positions 7, 11, 23, 24, 27, 28, and 31 is cyclohexylalanine, or at least one of the amino acid residues at positions 3, 16, 17, 18, 19, and 34 is .alpha.-aminoisobutyric acid; or, alternatively, at least the amino acid residue at position 1 is .alpha.,.beta.-diaminopropionic acid, the amino acid residue at position 27 is homoarginine, or the amino acid residue at position 31 is norleucine.Type: GrantFiled: January 7, 1997Date of Patent: October 19, 1999Assignee: Biomeasure, Inc.Inventor: Zheng Xin Dong
-
Patent number: 5877277Abstract: A linear (i.e., non-cyclic) analog of biologically active amphibian bombesin, mammalian gastrin-releasing peptide (GRP), or mammalian growth hormone releasing factor (GRF), having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell. Cleavage of a peptide bond in the active site of naturally occurring bombesin, GRP, or GRF is unnecessary for in vivo biological activity. The analog has one of the following modifications: (a) a deletion of an amino acid residue within the active site and a modification of an amino acid residue outside of the active site, (b) a replacement of two amino acid residues within the active site with a synthetic amino acid, a .beta.-amino acid, or a .gamma.-amino acid residue, or (c) a non-peptide bond instead of a peptide bond between an amino acid residue of the active site and an adjacent amino acid residue.Type: GrantFiled: November 10, 1994Date of Patent: March 2, 1999Assignees: Biomeasure, Inc., Administrators of the Tulane Educational FundInventors: David H. Coy, Jacques-Pierre Moreau, Sun Hyuk Kim
-
Patent number: 5767236Abstract: The invention features linear therapeutic peptides of the following formula: ##STR1## in which A.sup.1 is a D-.alpha.-aromatic amino acid or a D-.alpha.-tethered amino acid; A.sup.2 is Gln, His, 1-methyl-His, or 3-methyl-His; A.sup.3 is the D- or L-isomer selected from Nal, Trp, Phe, and p-X-Phe, where X is F, Cl, Br, NO.sub.2, OH or CH.sub.3 ; A.sup.4 is Ala, Val, Leu, Ile, Nle, or .alpha.-aminobutyric acid; A.sup.5 is Val, Ala, Leu, Ile, Nle, Thr, or .alpha.-aminobutyric acid; A.sup.6 is Gly, Sar, .beta.-Ala, or the D-isomer selected from Ala, N-methyl-Ala, Trp, and Nal; A.sup.7 is His, 1-methyl-His, 3-methyl-His, Lys, or .epsilon.-alkyl-Lys; A.sup.8 is Leu, Ile, Val, Nle, .alpha.-aminobutyric acid, Trp, Pro, Nal, Chx-Ala, Phe, or p-X-Phe, where X is F, Cl, Br, NO.sub.2, OH or CH.sub.3 ; A.sup.9 is Met, Met-oxide, Leu, Ile, Nle, .alpha.-aminobutyric acid, or Cys; each R.sub.1 and R.sub.2, independently, is H, C.sub.1-12 alkyl, C.sub.7-10 phenylalkyl, or COE.sub.1, where E.sub.1 is C.sub.1-20 alkyl, C.sub.Type: GrantFiled: February 13, 1995Date of Patent: June 16, 1998Assignee: Biomeasure, Inc.Inventors: Sun Hyuk Kim, Jacques-Pierre Moreau
-
Patent number: 5750646Abstract: A linear peptide which is an analog of a naturally occurring, biologically active peptide having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell, cleavage of a peptide bond in the active site to the naturally occurring peptide being unnecessary for in vivo biological activity, the analog having a non-peptide bond instead of a peptide bond between an amino acid of the active site and an adjacent amino acid, and having the same binding site as the naturally occurring peptide, so that the analog is capable of acting as a competitive inhibitor of the naturally occurring peptide by binding to the receptor and, by virtue of the non-peptide bond, failing to exhibit the in vivo activity of the naturally occurring peptide.Type: GrantFiled: March 22, 1995Date of Patent: May 12, 1998Assignees: The Administrators of the Tulane Educational Fund, Biomeasure, Inc.Inventors: David H. Coy, Jacques-Pierre Moreau, John E. Taylor, Sun Hyuk Kim
-
Patent number: 5739110Abstract: A method of promoting regeneration of hemopoietic cells in a subject undergoing chemotherapy or radiotherapy, which method includes the steps of (i) administering to the subject a first amount of AcSDKP or an agonist thereof, the first amount being effective to reduce the proliferation of hemopoietic cells during the chemotherapy or radiotherapy; (ii) administering to the subject a second amount of an angiotensin-converting enzyme (ACE) inhibitor, said second amount being effective to reduce the degradation of said AcSDKP or an agonist thereof by angiotensin-converting enzyme; and (iii) after the chemotherapy or radiotherapy, administering to the subject a second amount of a hemopoiesis growth factor, the second amount being effective to stimulate the proliferation of hemopoietic cells.Type: GrantFiled: February 1, 1996Date of Patent: April 14, 1998Assignees: Biomeasure Inc., Societe de Conseils de Recherches Et D'Applications ScientifiquesInventors: Arthur E. Bogden, Evelyn Deschamps De Paillette
-
Patent number: 5736517Abstract: A method of treating cancer in a human patient, the method involving administering to the patient a cancer cell inhibiting amount of an analog of a naturally occurring biologically active peptide or a fragment thereof, the peptide being one of mammalian gastrin-releasing peptide, neuromedin B, neuromedin C, amphibian bombesin, or litorin.Type: GrantFiled: June 8, 1993Date of Patent: April 7, 1998Assignee: Biomeasure, Inc.Inventors: Arthur E. Bogden, Jacques-Pierre Moreau
-
Patent number: 5723577Abstract: Peptide variants of fragment (1-34) of parathyroid hormone, in which at least one of the amino acid residues at positions 7, 11, 23, 24, 27, 28, and 31 is cyclohexylalanine, or at least one of the amino acid residues at positions 3, 16, 17, 18, 19, and 34 is .alpha.-aminoisobutyric acid; or, alternatively, at least the amino acid residue at position 1 is .alpha.,.beta.-diaminopropionic acid, the amino acid residue at position 27 is homoarginine, or the amino acid residue at position 31 is norleucine.Type: GrantFiled: March 29, 1996Date of Patent: March 3, 1998Assignee: Biomeasure Inc.Inventor: Zheng Xin Dong
-
Patent number: 5663295Abstract: Opioid peptides including those of the formula ##STR1## in which A.sub.1 is the identifying group of an amino acid selected from 3,4-dihydroxyphenylalanine, 3,4-dimethoxyphenylalanine, azatyrosine, and 2,6-dimethyltyrosine; A.sub.2 is the identifying group of an amino acid selected from D-Ala and D-Arg; A.sub.3 is H, or the identifying group of an amino acid selected from of 3,4-dihydroxyphenylalanine and 3,4-dimethoxyphenylalanine, A.sub.4 is H, cyclohexylmethyl, the identifying group of an amino acid selected from 3,4-dihydroxyphenylalanine, 3,4-dimethoxyphenylalanine, Phe, and substituted Phe with its benzene ring substituted by halogen, NO.sub.2, OH, or CH.sub.3 ; A.sub.5 is the identifying group of a D- or L-amino acid selected from Leu, Nle, Lys, Met and Met(O), or is deleted together with R.sub.4 --CH attached thereto; each R.sub.1 and R.sub.2 is --H, --C(NH.sub.2).dbd.NH, or C.sub.1-12 alkyl; R.sub.3 is ##STR2## R.sub.4 is ##STR3## and R.sub.5 is --(CH.sub.2).sub.Type: GrantFiled: December 8, 1994Date of Patent: September 2, 1997Assignee: Biomeasure Inc.Inventors: Jacques-Pierre Moreau, Sun Hyuk Kim, John E. Taylor
-
Patent number: 5569741Abstract: A cyclic octapeptide of the formula: ##STR1## wherein: A.sup.1 is D-Nal or D-Trp;A.sup.3 is Phe, F.sub.5 -Phe, or X-Phe wherein X is a halogen, NO.sub.2, CH.sub.3, or OH;A.sup.5 is --NH--CH(Y)--CO-- wherein Y is (CH.sub.2).sub.m --R.sub.4 --N(R.sub.5)(R.sub.6) or (CH.sub.2).sub.n --R.sub.4 --NH--C(R.sub.7)--N(R.sub.5) (R.sub.6);A.sup.6 is the D-- or L-- isomer of Thr, Leu, Ile, Nle, Val, and Abu;A.sup.8 is Nal or Trp;m is 1, 2, or 3;n is 1, 2, 3, 4 or 5;each of R.sub.1 and R.sub.2, independently, is H, E, COE, or COOE wherein E is C.sub.1-12 alkyl, C.sub.2-12 alkenyl, C.sub.2-12 alkynyl, phenyl, naphthyl, C.sub.7-12 phenylalkyl or alkylphenyl, C.sub.8-12 phenylalkenyl or alkenylphenyl, C.sub.8-12 phenylalkynyl or alkynylphenyl, C.sub.11-20 naphthylalkyl or alkylnaphthyl, C.sub.12-20 naphthylalkenyl or alkenylnaphthyl, or C.sub.12-20 naphthylalkynyl or alkynylnaphthyl, provided that when one of R.sub.1 or R.sub.2 is COE or COOE, the other must be H;R.sub.4 is C.sub.6 H.sub.4 or absent;R.sub.7 is .dbd.NR.sub.Type: GrantFiled: December 8, 1994Date of Patent: October 29, 1996Assignees: Biomeasure, Inc., The Administrators of the Tulane Educational FundInventors: David H. Coy, John E. Taylor
-
Patent number: 5552520Abstract: Peptide derivatives containing one or more substituents separately linked by an amide, amino or sulfonamide bond to an amino group on either the N-terminal end or side chain of a biologically active peptide moiety. The peptide derivatives have relatively enhanced biological activity when compared to the corresponding peptide alone.Type: GrantFiled: August 9, 1994Date of Patent: September 3, 1996Assignee: Biomeasure, Inc.Inventors: Sun H. Kim, Susan R. Keyes, Sylviane Moreau, Zheng X. Dong, John Taylor
-
Patent number: 5504069Abstract: A method for inhibiting in a mammal the accelerated growth of a solid primary or metastatic tumor resulting from tissue trauma caused surgically, non-surgically, or by tissue ulceration, which method comprises the step of administering to the mammal a therapeutically effective amount of somatostatin or a somatostatin agonist.Type: GrantFiled: February 11, 1993Date of Patent: April 2, 1996Assignee: Biomeasure, Inc.Inventors: Arthur E. Bogden, Jaques-Pierre Moreau
-
Patent number: 5462926Abstract: A method of selectively inhibiting biochemical activity of cells induced by neuromedin B. The method includes the step of contacting cells which contain neuromedin B receptor with a cyclic octapeptide, D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH.sub.2, or an analog thereof.Type: GrantFiled: June 17, 1993Date of Patent: October 31, 1995Assignees: Biomeasure, Inc., Administrators of the Tulane Educational FundInventors: David H. Coy, John E. Taylor